董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James M. Cornelius Chairman of the Board 82 55.00万美元 未持股 2017-02-27
Peter Kasper Jakobsen President and Chief Executive Officer,Director 54 719.62万美元 未持股 2017-02-27
Michael A. Sherman Director 59 28.61万美元 未持股 2017-02-27
Michael Grobstein Director 83 29.51万美元 未持股 2017-02-27
Anna C. Catalano Director 66 29.76万美元 未持股 2017-02-27
Kimberly A. Casiano Director 67 29.16万美元 未持股 2017-02-27
Steven M. Altschuler Director 71 30.03万美元 未持股 2017-02-27
Howard B. Bernick Director 72 29.63万美元 未持股 2017-02-27
Celeste A. Clark Director 72 28.91万美元 未持股 2017-02-27
Stephen W. Golsby Director 70 28.16万美元 未持股 2017-02-27
Peter G. Ratcliffe Director 77 30.16万美元 未持股 2017-02-27
Elliott Sigal Director 73 29.48万美元 未持股 2017-02-27
Robert S. Singer Director 73 30.01万美元 未持股 2017-02-27

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Peter Kasper Jakobsen President and Chief Executive Officer,Director 54 719.62万美元 未持股 2017-02-27
Michel Cup Executive Vice President and Chief Financial Officer 47 211.83万美元 未持股 2017-02-27
Ian E. Ormesher Senior Vice President, Global Human Resources 54 未披露 未持股 2017-02-27
Charles M. Urbain Executive Vice President and Chief Operating Officer 62 212.52万美元 未持股 2017-02-27
Dirk Hondmann Chief Scientific Officer 53 未披露 未持股 2017-02-27
James Jeffrey Jobe Senior Vice President, Global Operations 57 144.51万美元 未持股 2017-02-27
Patrick M. Sheller Senior Vice President, General Counsel and Secretary 55 222.64万美元 未持股 2017-02-27
James E. Shiah Senior Vice President, Finance and Controller 57 未披露 未持股 2017-02-27

董事简历

中英对照 |  中文 |  英文
James M. Cornelius

James M. Cornelius,自2020年9月起担任Mbx Biosciences, Inc.董事会成员。Cornelius先生是一位成功的全球生物制药领导者,也是公认的风险投资者和慈善家。此前,2008年2月至2015年5月,他担任Bristol Myers Squibb Co. (BMY,纽约证券交易所代码:BMY)董事会主席,2006年9月至2010年3月担任首席执行官。2009年12月至2017年6月,Cornelius先生担任Mead Johnson Nutrition(随后被Reckitt Benckiser收购)董事会主席。2005年11月至2006年4月,他担任Guidant Corporation(随后被Boston Scientific Corporation (NYSE: BSX)收购)的董事会主席兼首席执行官。此前,自1994年9月公司在Eli Lilly and Co. (NYSE: LLY)内成立以来,他担任Guidant Corporation的董事会执行主席和高级管理人员。1983年至1995年,他是Lilly公司的董事会成员和首席财务官。此外,他曾担任12家私人和上市公司的董事会成员,包括the Chubb Corporation、the DIRECTV Group和Given Imaging。他目前是Cornelius Family Foundation和Cornelius Private Investments的主席。他获得了密歇根州立大学的学士学位和工商管理硕士学位。


James M. Cornelius,has served on Mbx Biosciences, Inc. board of directors since September 2020. Mr. Cornelius is an accomplished global biopharmaceutical leader as well as a recognized venture investor and philanthropist. Previously, he served as Chairman of the Board of Bristol Myers Squibb Co., or BMY, (NYSE: BMY) from February 2008 to May 2015, and as Chief Executive Officer from September 2006 to March 2010. Mr. Cornelius served as Chairman of the Board of Mead Johnson Nutrition (subsequently acquired by Reckitt Benckiser) from December 2009 to June 2017. Mr. Cornelius served as Board Chairman and Chief Executive Officer of Guidant Corporation (subsequently acquired by Boston Scientific Corporation (NYSE: BSX)), from November 2005 to April 2006. Previously, he was executive Chairman of the Board of Guidant Corporation and its senior executive starting from September 1994 when the Company was formed within Eli Lilly and Co., or Eli Lilly, (NYSE: LLY). Mr. Cornelius was a member of Eli Lilly's Board of Directors and its Chief Financial Officer from 1983 until 1995. In addition, he has served on the Board of Directors of a dozen private and public companies, including The Chubb Corporation, The DIRECTV Group and Given Imaging. Mr. Cornelius is currently Chairman of Cornelius Family Foundation and Cornelius Private Investments. He earned a B.A. magna cum laude and M.B.A. from Michigan State University.
James M. Cornelius,自2020年9月起担任Mbx Biosciences, Inc.董事会成员。Cornelius先生是一位成功的全球生物制药领导者,也是公认的风险投资者和慈善家。此前,2008年2月至2015年5月,他担任Bristol Myers Squibb Co. (BMY,纽约证券交易所代码:BMY)董事会主席,2006年9月至2010年3月担任首席执行官。2009年12月至2017年6月,Cornelius先生担任Mead Johnson Nutrition(随后被Reckitt Benckiser收购)董事会主席。2005年11月至2006年4月,他担任Guidant Corporation(随后被Boston Scientific Corporation (NYSE: BSX)收购)的董事会主席兼首席执行官。此前,自1994年9月公司在Eli Lilly and Co. (NYSE: LLY)内成立以来,他担任Guidant Corporation的董事会执行主席和高级管理人员。1983年至1995年,他是Lilly公司的董事会成员和首席财务官。此外,他曾担任12家私人和上市公司的董事会成员,包括the Chubb Corporation、the DIRECTV Group和Given Imaging。他目前是Cornelius Family Foundation和Cornelius Private Investments的主席。他获得了密歇根州立大学的学士学位和工商管理硕士学位。
James M. Cornelius,has served on Mbx Biosciences, Inc. board of directors since September 2020. Mr. Cornelius is an accomplished global biopharmaceutical leader as well as a recognized venture investor and philanthropist. Previously, he served as Chairman of the Board of Bristol Myers Squibb Co., or BMY, (NYSE: BMY) from February 2008 to May 2015, and as Chief Executive Officer from September 2006 to March 2010. Mr. Cornelius served as Chairman of the Board of Mead Johnson Nutrition (subsequently acquired by Reckitt Benckiser) from December 2009 to June 2017. Mr. Cornelius served as Board Chairman and Chief Executive Officer of Guidant Corporation (subsequently acquired by Boston Scientific Corporation (NYSE: BSX)), from November 2005 to April 2006. Previously, he was executive Chairman of the Board of Guidant Corporation and its senior executive starting from September 1994 when the Company was formed within Eli Lilly and Co., or Eli Lilly, (NYSE: LLY). Mr. Cornelius was a member of Eli Lilly's Board of Directors and its Chief Financial Officer from 1983 until 1995. In addition, he has served on the Board of Directors of a dozen private and public companies, including The Chubb Corporation, The DIRECTV Group and Given Imaging. Mr. Cornelius is currently Chairman of Cornelius Family Foundation and Cornelius Private Investments. He earned a B.A. magna cum laude and M.B.A. from Michigan State University.
Peter Kasper Jakobsen

Peter Kasper Jakobsen,自2013年4月他一直是我们的总裁兼首席执行官,在此之前,他自2012年1月担任本公司执行副总裁兼首席运营官。他从2009年1月至2011年12月担任我们美洲地区的总裁,自1998年3月一直在Mead Johnson担任多个职位。从2006年10月至2009年1月,他担任亚太区高级副总裁。从2004年2月至2006年10月他担任南亚副总裁,从2001年6月至2004年6月,他担任菲律宾总经理。


Peter Kasper Jakobsen has been our President and Chief Executive Officer since April 2013 prior to which he served as the Company's executive vice president and chief operating officer since January 2012. Mr. Jakobsen previously had been our president, Americas from January 2009 through December 2011 and has been employed continuously by Mead Johnson since March 1998 in various capacities. From October 2006 to January 2009 he served as senior vice president, Asia Pacific. From February 2004 to October 2006 Mr. Jakobsen served as vice president, South Asia, and from June 2001 to June 2004 he served as general manager, Philippines.
Peter Kasper Jakobsen,自2013年4月他一直是我们的总裁兼首席执行官,在此之前,他自2012年1月担任本公司执行副总裁兼首席运营官。他从2009年1月至2011年12月担任我们美洲地区的总裁,自1998年3月一直在Mead Johnson担任多个职位。从2006年10月至2009年1月,他担任亚太区高级副总裁。从2004年2月至2006年10月他担任南亚副总裁,从2001年6月至2004年6月,他担任菲律宾总经理。
Peter Kasper Jakobsen has been our President and Chief Executive Officer since April 2013 prior to which he served as the Company's executive vice president and chief operating officer since January 2012. Mr. Jakobsen previously had been our president, Americas from January 2009 through December 2011 and has been employed continuously by Mead Johnson since March 1998 in various capacities. From October 2006 to January 2009 he served as senior vice president, Asia Pacific. From February 2004 to October 2006 Mr. Jakobsen served as vice president, South Asia, and from June 2001 to June 2004 he served as general manager, Philippines.
Michael A. Sherman

Michael A. Sherman,2006年10月起,他成为首席财务官;1994年12月至2006年10月,他担任过多个行政职务,其中距今最近的是2004年5月至2006年10月在Guidant Corporation(心血管疾病设备制造商,2006年4月被Boston Scientific Corporation这一医药设备公司收购)担任的财务部及策略规划部副总裁。他获有迪堡大学经济学学士学位以及达特茅斯商学院工商管理硕士学位。


Michael A. Sherman has served as President and Chief Executive Officer since June 2016. He served as Chief Financial Officer from October 2006 to February 2017 and as Chief Operating Officer from June 2014 to June 2016. From December 1994 to October 2006 Mr. Sherman served in various executive roles, but most recently as Vice President of Finance and Strategic Planning from May 2004 to October 2006 of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company, in April 2006. Mr. Sherman serves on the Board of Directors of Mead Johnson Nutrition Company, a pediatric nutrition company. He also serves on the Indianapolis Children's Museum Board of Trustees. Mr. Sherman holds a B.A. in economics from DePauw University and an M.B.A. from the Amos Tuck School, Dartmouth College.
Michael A. Sherman,2006年10月起,他成为首席财务官;1994年12月至2006年10月,他担任过多个行政职务,其中距今最近的是2004年5月至2006年10月在Guidant Corporation(心血管疾病设备制造商,2006年4月被Boston Scientific Corporation这一医药设备公司收购)担任的财务部及策略规划部副总裁。他获有迪堡大学经济学学士学位以及达特茅斯商学院工商管理硕士学位。
Michael A. Sherman has served as President and Chief Executive Officer since June 2016. He served as Chief Financial Officer from October 2006 to February 2017 and as Chief Operating Officer from June 2014 to June 2016. From December 1994 to October 2006 Mr. Sherman served in various executive roles, but most recently as Vice President of Finance and Strategic Planning from May 2004 to October 2006 of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company, in April 2006. Mr. Sherman serves on the Board of Directors of Mead Johnson Nutrition Company, a pediatric nutrition company. He also serves on the Indianapolis Children's Museum Board of Trustees. Mr. Sherman holds a B.A. in economics from DePauw University and an M.B.A. from the Amos Tuck School, Dartmouth College.
Michael Grobstein

Michael Grobstein,是安永会计师事务退休副会长,这是一家一个独立的注册会计师事务所。1964年至1998年,Grobstein先生曾任职于安永会计师事务所,并于1975年被任命为合伙人。1993年至1998年,他担任副会长,主管国际业务;1987年至1993年,担任副会长,主管策划、营销和产业服务;1984年至1987年,担任副会长,主管会计和审计业务。他现任受托人委员会和执行委员会,并且是中央公园保护协会的财务主管。他还任职于同行健康交流公司董事会。Grobstein先生还是美赞臣营养品公司董事。在过去的五年中,Grobstein先生是基文影像公司的主管。


Michael Grobstein retired as Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. He worked with Ernst & Young from 1964 until 1998 and was admitted as a partner in 1975. Mr. Grobstein served as a Vice Chairman-International Operations from 1993 until 1998 as Vice Chairman-Planning, Marketing and Industry Services from 1987 until 1993 and as Vice Chairman-Accounting and Auditing Services from 1984 until 1987. He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy. He also serves on the Board of Directors of the Peer Health Exchange, Inc. During the last five years, Mr. Grobstein was a Director of Mead Johnson Nutrition Company and Given Imaging Ltd.
Michael Grobstein,是安永会计师事务退休副会长,这是一家一个独立的注册会计师事务所。1964年至1998年,Grobstein先生曾任职于安永会计师事务所,并于1975年被任命为合伙人。1993年至1998年,他担任副会长,主管国际业务;1987年至1993年,担任副会长,主管策划、营销和产业服务;1984年至1987年,担任副会长,主管会计和审计业务。他现任受托人委员会和执行委员会,并且是中央公园保护协会的财务主管。他还任职于同行健康交流公司董事会。Grobstein先生还是美赞臣营养品公司董事。在过去的五年中,Grobstein先生是基文影像公司的主管。
Michael Grobstein retired as Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. He worked with Ernst & Young from 1964 until 1998 and was admitted as a partner in 1975. Mr. Grobstein served as a Vice Chairman-International Operations from 1993 until 1998 as Vice Chairman-Planning, Marketing and Industry Services from 1987 until 1993 and as Vice Chairman-Accounting and Auditing Services from 1984 until 1987. He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy. He also serves on the Board of Directors of the Peer Health Exchange, Inc. During the last five years, Mr. Grobstein was a Director of Mead Johnson Nutrition Company and Given Imaging Ltd.
Anna C. Catalano

Anna C. Catalano,她拥有超过30年的企业工作经验,其中超过20年花在能源行业,担任各种市场营销,运营和业务发展职务。她担任最近的职务是在2000年至2003年在英国石油公司担任市场集团副总裁,1999至2000年担任新兴市场的集团副总裁。她曾在亚洲,欧洲和美国担任过一些高级行政职位,包括中国的阿莫科东方石油公司总裁,阿莫科美国零售业务的高级副总裁。她目前担任Willis控股集团董事,在那里她还担任了Chemtura公司赔偿和治理委员会委员,还担任环境,健康和安全委员会及薪酬委员会委员和科腾高性能聚合物的董事,在科腾她担任薪酬委员会委员。她曾担任Hercules公司和SSL国际有限公司的董事。她在阿尔茨海默氏症协会全国委员会担任主任,在西北大学担任凯洛格创新网络的高级研究员和顾问委员会成员。


Anna C. Catalano was appointed to the Board of Directors of the Company in September 2018 and serves as a member of Compensation Committee. From 1979 until her retirement in 2003 Ms. Catalano served in various leadership roles at BP p.l.c., a global energy producer, and its predecessor Amoco Corporation. Most recently, from 2000 to 2003 she served as Group Vice President, Global Marketing, for BP p.l.c. Ms. Catalano has significant international business experience, having served as President of Amoco Orient Oil Company, including two years during which she lived in Beijing. Ms. Catalano has served on the board of directors and compensation committee of Kraton Corporation, a global producer of bio-based chemicals and specialty polymers, since 2011; on the board of directors of Willis Towers Watson p.l.c., a global risk advisory, broking, and solutions company, since 2016 having previously served on the board of directors of Willis Group from 2006 until the merger of Willis Group and Towers Watson & Co.; and on the board of directors and compensation committee of HollyFrontier Corporation, a petroleum refiner, since November 2017. Ms. Catalano previously served on the boards of Mead Johnson Nutrition Co. until May 2017 and Chemtura Corp. until June 2017.
Anna C. Catalano,她拥有超过30年的企业工作经验,其中超过20年花在能源行业,担任各种市场营销,运营和业务发展职务。她担任最近的职务是在2000年至2003年在英国石油公司担任市场集团副总裁,1999至2000年担任新兴市场的集团副总裁。她曾在亚洲,欧洲和美国担任过一些高级行政职位,包括中国的阿莫科东方石油公司总裁,阿莫科美国零售业务的高级副总裁。她目前担任Willis控股集团董事,在那里她还担任了Chemtura公司赔偿和治理委员会委员,还担任环境,健康和安全委员会及薪酬委员会委员和科腾高性能聚合物的董事,在科腾她担任薪酬委员会委员。她曾担任Hercules公司和SSL国际有限公司的董事。她在阿尔茨海默氏症协会全国委员会担任主任,在西北大学担任凯洛格创新网络的高级研究员和顾问委员会成员。
Anna C. Catalano was appointed to the Board of Directors of the Company in September 2018 and serves as a member of Compensation Committee. From 1979 until her retirement in 2003 Ms. Catalano served in various leadership roles at BP p.l.c., a global energy producer, and its predecessor Amoco Corporation. Most recently, from 2000 to 2003 she served as Group Vice President, Global Marketing, for BP p.l.c. Ms. Catalano has significant international business experience, having served as President of Amoco Orient Oil Company, including two years during which she lived in Beijing. Ms. Catalano has served on the board of directors and compensation committee of Kraton Corporation, a global producer of bio-based chemicals and specialty polymers, since 2011; on the board of directors of Willis Towers Watson p.l.c., a global risk advisory, broking, and solutions company, since 2016 having previously served on the board of directors of Willis Group from 2006 until the merger of Willis Group and Towers Watson & Co.; and on the board of directors and compensation committee of HollyFrontier Corporation, a petroleum refiner, since November 2017. Ms. Catalano previously served on the boards of Mead Johnson Nutrition Co. until May 2017 and Chemtura Corp. until June 2017.
Kimberly A. Casiano

Kimberly A. Casiano, 2010年1月1日,她成立了金佰利卡西亚诺联合公司,在那里她担任总裁。公司提供营销、招聘、沟通、宣传和多样性的咨询服务,主要目标市场为美国西班牙裔市场、加勒比海地区和拉丁美洲。1994年至2009年12月31日,她担任卡西亚诺通信公司(一家出版和直接营销公司)的总裁兼首席运营官。1987年到1994年,她担任一系列的的管理职位,在卡西亚诺通信期刊和杂志,双语直销和呼叫中心部门。她是美国共同银行,波多黎各丰业银行、西班牙裔奖学金基金会的董事会成员。


Kimberly A. Casiano,has been the President of Kimberly Casiano & Associates since 2010. Her firm provides advisory services in marketing, recruiting, communications, advocacy, and diversity. From 1994 through 2009, Ms. Casiano served as President and Chief Operating Officer of Casiano Communications, Inc., a U.S. Hispanic media and direct marketing company. She joined the company in 1987 and held various management positions. Prior to that, Ms. Casiano was a consultant in the Caribbean and Latin America for the U.S. Agency for International Development (A.I.D.) of the U.S. Department of State, focusing on economic development, trade, and investment promotion programs. Ms. Casiano is a member of the founding Board of Directors of the Latino Corporate Directors Association, the global Alumni Board of Harvard Business School, and the Board of Advisors of Moffitt Cancer Center in Tampa. Ms. Casiano also serves as a director of Federal Home Loan Bank of Atlanta.
Kimberly A. Casiano, 2010年1月1日,她成立了金佰利卡西亚诺联合公司,在那里她担任总裁。公司提供营销、招聘、沟通、宣传和多样性的咨询服务,主要目标市场为美国西班牙裔市场、加勒比海地区和拉丁美洲。1994年至2009年12月31日,她担任卡西亚诺通信公司(一家出版和直接营销公司)的总裁兼首席运营官。1987年到1994年,她担任一系列的的管理职位,在卡西亚诺通信期刊和杂志,双语直销和呼叫中心部门。她是美国共同银行,波多黎各丰业银行、西班牙裔奖学金基金会的董事会成员。
Kimberly A. Casiano,has been the President of Kimberly Casiano & Associates since 2010. Her firm provides advisory services in marketing, recruiting, communications, advocacy, and diversity. From 1994 through 2009, Ms. Casiano served as President and Chief Operating Officer of Casiano Communications, Inc., a U.S. Hispanic media and direct marketing company. She joined the company in 1987 and held various management positions. Prior to that, Ms. Casiano was a consultant in the Caribbean and Latin America for the U.S. Agency for International Development (A.I.D.) of the U.S. Department of State, focusing on economic development, trade, and investment promotion programs. Ms. Casiano is a member of the founding Board of Directors of the Latino Corporate Directors Association, the global Alumni Board of Harvard Business School, and the Board of Advisors of Moffitt Cancer Center in Tampa. Ms. Casiano also serves as a director of Federal Home Loan Bank of Atlanta.
Steven M. Altschuler

Steven M. Altschuler,他目前是费城儿童医院的首席执行官,他自2000年4月起担任该职位,自2012年9月他曾担任Weight Watchers国际公司的董事,并担任其审计和薪酬委员会委员。他还担任Spark Therapeutics公司的董事会主席,并担任费城自由图书馆,全球疫苗与免疫运动和大学医院协会的董事会成员。


Steven M. Altschuler,has been a director since September 2012. Dr. Altschuler has served as the Chief Executive Officer and Chair of the board of directors of Corner Therapeutics, Inc., a private immunotherapy company, since September 2020, and as Managing Director, Healthcare Ventures of Ziff Capital Partners, a private investment firm, since May 2018. He previously served as a consultant to the University of Miami Health Care System from September 2017 through December 2017, the Chief Executive Officer of the University of Miami Health Care System and Executive Vice President for Healthcare at the University of Miami from January 2016 to September 2017, and the Chief Executive Officer of The Children's Hospital of Philadelphia (CHOP) from April 2000 until June 2015. Prior to assuming the role of Chief Executive Officer, Dr. Altschuler held several positions at CHOP and the Perelman School of Medicine at the University of Pennsylvania, including Physician-in-Chief/Chair of Pediatrics and chief of the Division of Gastroenterology, Hepatology and Nutrition. Dr. Altschuler received a B.A. in mathematics and an M.D. from Case Western Reserve University. Dr. Altschuler is Chairman of the board of directors of 89bio, Inc. and Lexeo Therapeutics, Inc. He previously served as a director of Adtalem Global Education Inc. and Orchard Therapeutics plc.
Steven M. Altschuler,他目前是费城儿童医院的首席执行官,他自2000年4月起担任该职位,自2012年9月他曾担任Weight Watchers国际公司的董事,并担任其审计和薪酬委员会委员。他还担任Spark Therapeutics公司的董事会主席,并担任费城自由图书馆,全球疫苗与免疫运动和大学医院协会的董事会成员。
Steven M. Altschuler,has been a director since September 2012. Dr. Altschuler has served as the Chief Executive Officer and Chair of the board of directors of Corner Therapeutics, Inc., a private immunotherapy company, since September 2020, and as Managing Director, Healthcare Ventures of Ziff Capital Partners, a private investment firm, since May 2018. He previously served as a consultant to the University of Miami Health Care System from September 2017 through December 2017, the Chief Executive Officer of the University of Miami Health Care System and Executive Vice President for Healthcare at the University of Miami from January 2016 to September 2017, and the Chief Executive Officer of The Children's Hospital of Philadelphia (CHOP) from April 2000 until June 2015. Prior to assuming the role of Chief Executive Officer, Dr. Altschuler held several positions at CHOP and the Perelman School of Medicine at the University of Pennsylvania, including Physician-in-Chief/Chair of Pediatrics and chief of the Division of Gastroenterology, Hepatology and Nutrition. Dr. Altschuler received a B.A. in mathematics and an M.D. from Case Western Reserve University. Dr. Altschuler is Chairman of the board of directors of 89bio, Inc. and Lexeo Therapeutics, Inc. He previously served as a director of Adtalem Global Education Inc. and Orchard Therapeutics plc.
Howard B. Bernick

Howard B. Bernick自2012年10月以来担任Trupanion运营的副总裁。之前,他从1997年6月到2012年8月担任Allianz Insurance plc的运营经理和其他各种角色。


Howard B. Bernick is currently the president of Bernick Advisory Limited, a private investment advisory company, and has served in such a role since November 2006. From November 1994 to November 2006 Mr. Bernick served as president and chief executive officer and a director of Alberto-Culver Company, a global branded consumer products and beauty supply distribution company. From August 2001 through October 2008 Mr. Bernick served as a director of the Wm. Wrigley Jr. Company, a global confectionery company, until its acquisition by Mars Inc. Mr. Bernick serves on the board of directors of The Duchossois Group, Inc., is a member of the board of trustees of The Field Museum in Chicago and serves as a director of the Juvenile Diabetes Research Foundation.
Howard B. Bernick自2012年10月以来担任Trupanion运营的副总裁。之前,他从1997年6月到2012年8月担任Allianz Insurance plc的运营经理和其他各种角色。
Howard B. Bernick is currently the president of Bernick Advisory Limited, a private investment advisory company, and has served in such a role since November 2006. From November 1994 to November 2006 Mr. Bernick served as president and chief executive officer and a director of Alberto-Culver Company, a global branded consumer products and beauty supply distribution company. From August 2001 through October 2008 Mr. Bernick served as a director of the Wm. Wrigley Jr. Company, a global confectionery company, until its acquisition by Mars Inc. Mr. Bernick serves on the board of directors of The Duchossois Group, Inc., is a member of the board of trustees of The Field Museum in Chicago and serves as a director of the Juvenile Diabetes Research Foundation.
Celeste A. Clark

Celeste A. Clark是Abraham Clark Consulting的独立董事和负责人,该公司是她于2011年创立的健康和监管政策咨询公司。她在全球公共政策和可持续发展方面拥有丰富的经验,此前曾在家乐氏公司担任公共政策全球主管兼首席可持续发展官(2004-2011年),在那里她领导了180个市场的健康/营养计划,并建立了公司的可持续发展框架,以及The Simply Good Foods Company,此前曾在AdvantAge Health Holdings和Omega Protein Corporation等董事会任职。


Celeste A. Clark has been a director since September 2017. Dr. Clark has been the principal of Abraham Clark Consulting, LLC, a consulting firm, since November 2011 and consults on nutrition and health policy, regulatory affairs and leadership development. Dr. Clark is an adjunct professor at Michigan State University where she earned her doctorate in Food Science and was also recently bestod an honorary doctorate of Humanities for her community engagement work. She previoly served as Senior Vice President, Global Policy and External Affairs of Kellogg Company, a food manufacturing company, and was the Chief Stainability Officer until she retired in 2011. She was a member of the Global Executive Management Team and had an accomplished career spanning nearly 35 years in the food indtry. At Kellogg Company, she was responsible for the development and implementation of health, nutrition and regulatory science initiatives globally to ensure consistency in approach and implementation. In addition, she also led global corporate communications, government relations, philanthropy and several administrative functions. Dr. Clark serves as an independent director on boards of public, private and not for profit entities. She was recently recognized as a Directorship 100 honoree by the National Association of Corporate Directors in 2023 and was recognized as one of "100 Black Board Members Making a Difference" by BoardProspects in 2024.
Celeste A. Clark是Abraham Clark Consulting的独立董事和负责人,该公司是她于2011年创立的健康和监管政策咨询公司。她在全球公共政策和可持续发展方面拥有丰富的经验,此前曾在家乐氏公司担任公共政策全球主管兼首席可持续发展官(2004-2011年),在那里她领导了180个市场的健康/营养计划,并建立了公司的可持续发展框架,以及The Simply Good Foods Company,此前曾在AdvantAge Health Holdings和Omega Protein Corporation等董事会任职。
Celeste A. Clark has been a director since September 2017. Dr. Clark has been the principal of Abraham Clark Consulting, LLC, a consulting firm, since November 2011 and consults on nutrition and health policy, regulatory affairs and leadership development. Dr. Clark is an adjunct professor at Michigan State University where she earned her doctorate in Food Science and was also recently bestod an honorary doctorate of Humanities for her community engagement work. She previoly served as Senior Vice President, Global Policy and External Affairs of Kellogg Company, a food manufacturing company, and was the Chief Stainability Officer until she retired in 2011. She was a member of the Global Executive Management Team and had an accomplished career spanning nearly 35 years in the food indtry. At Kellogg Company, she was responsible for the development and implementation of health, nutrition and regulatory science initiatives globally to ensure consistency in approach and implementation. In addition, she also led global corporate communications, government relations, philanthropy and several administrative functions. Dr. Clark serves as an independent director on boards of public, private and not for profit entities. She was recently recognized as a Directorship 100 honoree by the National Association of Corporate Directors in 2023 and was recognized as one of "100 Black Board Members Making a Difference" by BoardProspects in 2024.
Stephen W. Golsby

Stephen W. Golsby,他从2008年9月直到他2013年4月退休作为我们的总裁兼首席执行官。在担任总裁兼首席执行官之前,他自1997年10月一直在Mead Johnson担任各种职务。从2004年1月至2008年9月他曾担任Mead Johnson总裁。他自2001年至2003年担任Mead Johnson国际;1998年至2000年担任亚太区高级副总裁。他担任Beam公司董事,该公司宣布了被Suntory Holdings Limited公司收购的最终协议。 他担任Masan Consumer(越南)的董事,还担任了泰盟冷冻产品和泰国投资委员会顾问。


Stephen W. Golsby served, from September 2008 until his retirement in April 2013 as our president and chief executive officer. Prior to serving as president and chief executive officer, he was employed continuously by Mead Johnson in various capacities since October 1997. From January 2004 to September 2008 Mr. Golsby served as president of Mead Johnson. He served as president, International of Mead Johnson from 2001 until 2003 and senior vice president, Asia Pacific from 1998 to 2000. Mr. Golsby served as a director of Beam Inc. until its 2014 acquisition by Suntory Holdings Limited. Mr. Golsby is a director of RMA Group Hong Kong and also serves as an advisor to Thai Union Group, Thai Wah pcl and to the Thailand Board of Investment.
Stephen W. Golsby,他从2008年9月直到他2013年4月退休作为我们的总裁兼首席执行官。在担任总裁兼首席执行官之前,他自1997年10月一直在Mead Johnson担任各种职务。从2004年1月至2008年9月他曾担任Mead Johnson总裁。他自2001年至2003年担任Mead Johnson国际;1998年至2000年担任亚太区高级副总裁。他担任Beam公司董事,该公司宣布了被Suntory Holdings Limited公司收购的最终协议。 他担任Masan Consumer(越南)的董事,还担任了泰盟冷冻产品和泰国投资委员会顾问。
Stephen W. Golsby served, from September 2008 until his retirement in April 2013 as our president and chief executive officer. Prior to serving as president and chief executive officer, he was employed continuously by Mead Johnson in various capacities since October 1997. From January 2004 to September 2008 Mr. Golsby served as president of Mead Johnson. He served as president, International of Mead Johnson from 2001 until 2003 and senior vice president, Asia Pacific from 1998 to 2000. Mr. Golsby served as a director of Beam Inc. until its 2014 acquisition by Suntory Holdings Limited. Mr. Golsby is a director of RMA Group Hong Kong and also serves as an advisor to Thai Union Group, Thai Wah pcl and to the Thailand Board of Investment.
Peter G. Ratcliffe

Peter G. Ratcliffe,他曾担任Carnival Corporation and PLC(全球邮轮公司)的the P&O Princess国际部门的首席执行官。从2000年1月到2003年4月,他曾担任Carnival公司(全球邮轮公司)的首席执行官。他是BBA Aviation公司,以及Casa Pacifica Centers for Children & Families的董事。他此前曾担任Carnival Corporation and PLC的董事(2013年4月),也是Peninsula and Steam Navigation Company的前任董事。他是the Institute of Chartered Accountants in England & Wales的成员。


Peter G. Ratcliffe served, from April 2003 until his retirement in June 2007 as chief executive officer of the P&O Princess International division of Carnival Corporation and plc, a global cruise company. From January 2000 to April 2003 he served as chief executive officer of P&O Princess Cruises plc, a global cruise company. Mr. Ratcliffe is a director of BBA Aviation plc and Casa Pacifica Centers for Children & Families. Mr. Ratcliffe is a fellow of the Institute of Chartered Accountants in England and Wales.
Peter G. Ratcliffe,他曾担任Carnival Corporation and PLC(全球邮轮公司)的the P&O Princess国际部门的首席执行官。从2000年1月到2003年4月,他曾担任Carnival公司(全球邮轮公司)的首席执行官。他是BBA Aviation公司,以及Casa Pacifica Centers for Children & Families的董事。他此前曾担任Carnival Corporation and PLC的董事(2013年4月),也是Peninsula and Steam Navigation Company的前任董事。他是the Institute of Chartered Accountants in England & Wales的成员。
Peter G. Ratcliffe served, from April 2003 until his retirement in June 2007 as chief executive officer of the P&O Princess International division of Carnival Corporation and plc, a global cruise company. From January 2000 to April 2003 he served as chief executive officer of P&O Princess Cruises plc, a global cruise company. Mr. Ratcliffe is a director of BBA Aviation plc and Casa Pacifica Centers for Children & Families. Mr. Ratcliffe is a fellow of the Institute of Chartered Accountants in England and Wales.
Elliott Sigal

Elliott Sigal,是百时美施贵宝公司的前执行副总裁兼董事。他于1997年加入BMS,并在研究和发展领域担任有越来越多的责任的工作。他自2004年至2013年退休担任BMS首席研发官和研发总裁。他担任于2011年BMS董事,直到2013年退休。他曾从2002年到2011年担任普林斯顿医疗系统委员会委员。他目前担任新企业协会高级顾问的企业集团医疗团队顾问,是各种生物技术公司顾问。此外,他担任Spark Therapeutics公司的董事,也担任民间非营利基金会,黑色素瘤研究联盟的董事会成员。


Elliott Sigal has served on our Board since January 2014. Dr. Sigal served as Chief Scientific Officer of Bristol-Myers Squibb, or BMS, from October 2004 until his retirement in June 2013 and was a member of the board of directors from March 2011 to June2013. Dr. Sigal joined BMS in 1997 and held positions of increasing responsibility in drug discovery and development and was a member of the executive committee from September 2001 through June 2013. Prior to BMS, he was Vice President of R&D and Chief Executive Officer for the genomics firm Mercator Genetics Inc. Dr. Sigal currently serves as a member of the board of directors for Adaptimmune Therapeutics plc, a role he has held since 2014. In addition, Dr. Sigal is an advisor to the life sciences venture firm New Enterprise Associates and consults for select biopharmaceutical companies. Dr. Sigal holds B.S., M.S. and Ph.D. degrees in industrial engineering from Purdue University and an M.D. from the University of Chicago. He completed his training in internal medicine and pulmonary medicine at the University of California, San Francisco, or UCSF. He received his research training at the Cardiovascular Research Institute at UCSF, where he served on the faculty of the UCSF Department of Medicine.
Elliott Sigal,是百时美施贵宝公司的前执行副总裁兼董事。他于1997年加入BMS,并在研究和发展领域担任有越来越多的责任的工作。他自2004年至2013年退休担任BMS首席研发官和研发总裁。他担任于2011年BMS董事,直到2013年退休。他曾从2002年到2011年担任普林斯顿医疗系统委员会委员。他目前担任新企业协会高级顾问的企业集团医疗团队顾问,是各种生物技术公司顾问。此外,他担任Spark Therapeutics公司的董事,也担任民间非营利基金会,黑色素瘤研究联盟的董事会成员。
Elliott Sigal has served on our Board since January 2014. Dr. Sigal served as Chief Scientific Officer of Bristol-Myers Squibb, or BMS, from October 2004 until his retirement in June 2013 and was a member of the board of directors from March 2011 to June2013. Dr. Sigal joined BMS in 1997 and held positions of increasing responsibility in drug discovery and development and was a member of the executive committee from September 2001 through June 2013. Prior to BMS, he was Vice President of R&D and Chief Executive Officer for the genomics firm Mercator Genetics Inc. Dr. Sigal currently serves as a member of the board of directors for Adaptimmune Therapeutics plc, a role he has held since 2014. In addition, Dr. Sigal is an advisor to the life sciences venture firm New Enterprise Associates and consults for select biopharmaceutical companies. Dr. Sigal holds B.S., M.S. and Ph.D. degrees in industrial engineering from Purdue University and an M.D. from the University of Chicago. He completed his training in internal medicine and pulmonary medicine at the University of California, San Francisco, or UCSF. He received his research training at the Cardiovascular Research Institute at UCSF, where he served on the faculty of the UCSF Department of Medicine.
Robert S. Singer

Robert S. Singer, 他自2006年1月至2009年4月担任Barilla Holding S.p.A公司(一个主要的意大利食品公司)的首席执行官,从2004年5月至2005年8月担任Abercrombie&Fitch公司(一个美国服装零售商)的总裁兼首席运营官。 2005年9月和2005年12月间,他一直在选择自己的下一个职位。加盟Abercrombie之前,他从1995年9月至2004年4月担任Gucci集团(一家领先的奢侈品公司)财务总监。他自2012年5月,担任过蒂芙尼公司的董事担任审计委员会主席。他由2006年4月至2010年4月也担任科蒂集团的董事及审计委员会主席。他从2003年到2006年担任Barilla Holding S.p.A公司薪酬委员会主席和董事。他2004至2006年担任Fairmont Hotels & Resorts公司董事和审计委员会董事长。他目前担任多家非上市公司的董事会成员。


Robert S. Singer,joined the Board in 2010, and currently serves as Chair of the Audit and Finance Committee. From May 31, 2020 to June 13, 2023, he served as Lead Independent Director. From 2006 to 2009 he served as Chief Executive Officer of Barilla Holding S.p.A., an Italian food company, and before that, he served as the President and Chief Operating Officer of Abercrombie and Fitch Co. from 2004 to 2005. He served as Chief Financial Officer of Gucci Group N.V. from 1995 to 2004. Mr. Singer started his career at Coopers & Lybrand in 1977. Mr. Singer also served as a director of Gianni Versace S.p.A. from 2009 to December 2016 and served as a director of Mead Johnson Nutrition from 2009 to June 2017. He has also served as a director and chair of the audit committees of Swarovksi International Holding SA since 2021, Tiffany & Co. from 2012 to 2021, Keurig Dr. Pepper Inc. since July 2018, and Panera Bread Company since September 2017 and provides similar services to certain private companies affiliated with JAB Group. From 2019 to 2022, Mr. Singer served as a member of the board of the private fashion company, Acne Studios, and continues to provide consulting services to the company. Mr. Singer has served as an advisor to the private equity firm IDG Capital, a private equity firm, since November 2018, and served as a senior advisor to CCMP Capital Advisors, LLC from 2011 to January 2016. He also served as a director and Chairman of the audit committee of Jimmy Choo PLC from September 2014 to 2017. He received a Bachelor of Arts Humanities degree from Johns Hopkins University, a Master of Arts degree in Comparative Literature from University of California, Irvine and graduated from New York University with a Master of Science in Accounting.
Robert S. Singer, 他自2006年1月至2009年4月担任Barilla Holding S.p.A公司(一个主要的意大利食品公司)的首席执行官,从2004年5月至2005年8月担任Abercrombie&Fitch公司(一个美国服装零售商)的总裁兼首席运营官。 2005年9月和2005年12月间,他一直在选择自己的下一个职位。加盟Abercrombie之前,他从1995年9月至2004年4月担任Gucci集团(一家领先的奢侈品公司)财务总监。他自2012年5月,担任过蒂芙尼公司的董事担任审计委员会主席。他由2006年4月至2010年4月也担任科蒂集团的董事及审计委员会主席。他从2003年到2006年担任Barilla Holding S.p.A公司薪酬委员会主席和董事。他2004至2006年担任Fairmont Hotels & Resorts公司董事和审计委员会董事长。他目前担任多家非上市公司的董事会成员。
Robert S. Singer,joined the Board in 2010, and currently serves as Chair of the Audit and Finance Committee. From May 31, 2020 to June 13, 2023, he served as Lead Independent Director. From 2006 to 2009 he served as Chief Executive Officer of Barilla Holding S.p.A., an Italian food company, and before that, he served as the President and Chief Operating Officer of Abercrombie and Fitch Co. from 2004 to 2005. He served as Chief Financial Officer of Gucci Group N.V. from 1995 to 2004. Mr. Singer started his career at Coopers & Lybrand in 1977. Mr. Singer also served as a director of Gianni Versace S.p.A. from 2009 to December 2016 and served as a director of Mead Johnson Nutrition from 2009 to June 2017. He has also served as a director and chair of the audit committees of Swarovksi International Holding SA since 2021, Tiffany & Co. from 2012 to 2021, Keurig Dr. Pepper Inc. since July 2018, and Panera Bread Company since September 2017 and provides similar services to certain private companies affiliated with JAB Group. From 2019 to 2022, Mr. Singer served as a member of the board of the private fashion company, Acne Studios, and continues to provide consulting services to the company. Mr. Singer has served as an advisor to the private equity firm IDG Capital, a private equity firm, since November 2018, and served as a senior advisor to CCMP Capital Advisors, LLC from 2011 to January 2016. He also served as a director and Chairman of the audit committee of Jimmy Choo PLC from September 2014 to 2017. He received a Bachelor of Arts Humanities degree from Johns Hopkins University, a Master of Arts degree in Comparative Literature from University of California, Irvine and graduated from New York University with a Master of Science in Accounting.

高管简历

中英对照 |  中文 |  英文
Peter Kasper Jakobsen

Peter Kasper Jakobsen,自2013年4月他一直是我们的总裁兼首席执行官,在此之前,他自2012年1月担任本公司执行副总裁兼首席运营官。他从2009年1月至2011年12月担任我们美洲地区的总裁,自1998年3月一直在Mead Johnson担任多个职位。从2006年10月至2009年1月,他担任亚太区高级副总裁。从2004年2月至2006年10月他担任南亚副总裁,从2001年6月至2004年6月,他担任菲律宾总经理。


Peter Kasper Jakobsen has been our President and Chief Executive Officer since April 2013 prior to which he served as the Company's executive vice president and chief operating officer since January 2012. Mr. Jakobsen previously had been our president, Americas from January 2009 through December 2011 and has been employed continuously by Mead Johnson since March 1998 in various capacities. From October 2006 to January 2009 he served as senior vice president, Asia Pacific. From February 2004 to October 2006 Mr. Jakobsen served as vice president, South Asia, and from June 2001 to June 2004 he served as general manager, Philippines.
Peter Kasper Jakobsen,自2013年4月他一直是我们的总裁兼首席执行官,在此之前,他自2012年1月担任本公司执行副总裁兼首席运营官。他从2009年1月至2011年12月担任我们美洲地区的总裁,自1998年3月一直在Mead Johnson担任多个职位。从2006年10月至2009年1月,他担任亚太区高级副总裁。从2004年2月至2006年10月他担任南亚副总裁,从2001年6月至2004年6月,他担任菲律宾总经理。
Peter Kasper Jakobsen has been our President and Chief Executive Officer since April 2013 prior to which he served as the Company's executive vice president and chief operating officer since January 2012. Mr. Jakobsen previously had been our president, Americas from January 2009 through December 2011 and has been employed continuously by Mead Johnson since March 1998 in various capacities. From October 2006 to January 2009 he served as senior vice president, Asia Pacific. From February 2004 to October 2006 Mr. Jakobsen served as vice president, South Asia, and from June 2001 to June 2004 he served as general manager, Philippines.
Michel Cup

Michel Cup,2015年9月以来,他一直担任我们的执行副总裁和首席财务官。加入公司之前,他曾担任D.E Master Blenders 1753(一个国际咖啡和茶业务,总部设在荷兰)的首席财务官(始于2015年1月)。加入D.E Master Blenders 1753公司之前,他曾担任Provimi公司的首席财务官(从2010年到2011年),以及Akzonobel公司的负责欧洲装饰涂料业务的财务主管(2009年至2010年)。他也曾担任高级财务职务,负责Numico公司的婴儿营养和医疗业务(1999年至2008年),包括Baby Nutrition Asia Pacific公司的首席财务官。他的职业生涯始于任职Deloitte公司,在那里他曾担任多种审计会计职务(1993年至1999年)。


Michel Cup has been our Executive Vice President and Chief Financial Officer since September 2015. Before joining the Company, through January 2015 Mr. Cup was the Chief Financial Officer CFO of D.E Master Blenders 1753 an international coffee and tea business headquartered in the Netherlands. Prior to joining D.E. Master Blenders 1753 Mr. Cup served as Chief Financial Officer of Provimi from 2010-2011 and as Finance Director of Akzonobel’s Decorative Paints business in Europe from 2009-2010. Mr. Cup has also held senior finance roles in Numico’s Baby and Medical Nutrition business from 1999-2008 including CFO Baby Nutrition Asia Pacific. Mr. Cup began his career with Deloitte where he held various audit and accounting roles from 1993-1999.
Michel Cup,2015年9月以来,他一直担任我们的执行副总裁和首席财务官。加入公司之前,他曾担任D.E Master Blenders 1753(一个国际咖啡和茶业务,总部设在荷兰)的首席财务官(始于2015年1月)。加入D.E Master Blenders 1753公司之前,他曾担任Provimi公司的首席财务官(从2010年到2011年),以及Akzonobel公司的负责欧洲装饰涂料业务的财务主管(2009年至2010年)。他也曾担任高级财务职务,负责Numico公司的婴儿营养和医疗业务(1999年至2008年),包括Baby Nutrition Asia Pacific公司的首席财务官。他的职业生涯始于任职Deloitte公司,在那里他曾担任多种审计会计职务(1993年至1999年)。
Michel Cup has been our Executive Vice President and Chief Financial Officer since September 2015. Before joining the Company, through January 2015 Mr. Cup was the Chief Financial Officer CFO of D.E Master Blenders 1753 an international coffee and tea business headquartered in the Netherlands. Prior to joining D.E. Master Blenders 1753 Mr. Cup served as Chief Financial Officer of Provimi from 2010-2011 and as Finance Director of Akzonobel’s Decorative Paints business in Europe from 2009-2010. Mr. Cup has also held senior finance roles in Numico’s Baby and Medical Nutrition business from 1999-2008 including CFO Baby Nutrition Asia Pacific. Mr. Cup began his career with Deloitte where he held various audit and accounting roles from 1993-1999.
Ian E. Ormesher

Ian E. Ormesher,他曾一直担任高级副总裁,负责全球人力资源(2014年9月以来)。加入公司之前,他曾担任Carlsberg Breweries A/S的西欧人力资源副总裁(从2012年10月到2014年9月)。从2011年1月到2012年9月,他曾担任Carlsberg Breweries公司的副总裁,负责亚洲人力资源。此前,他曾任职SABMiller公司12年,在那里他曾担任多种人力资源和组织开发职务,并不断被提拔,包括中国企业人力资源董事,最终担任集团营销董事(2008年10月至2011年1月)。


Ian E. Ormesher has been our Senior Vice President, Global Human Resources since September 2014. Before joining the Company, Mr. Ormesher served as the Vice President, Human Resources - Western Europe at Carlsberg Breweries A/S from October 2012 to September 2014. From January 2011 to September 2012 he was the Vice President, Human Resources - Asia at Carlsberg Breweries. Prior to that time, Mr. Ormesher spent 12 years with SABMiller, where he served in a variety of HR and organizational development roles of increasing responsibility, including as HR Director of its business in China, and ultimately as its Group Marketing Capability Director from October 2008 to January 2011.
Ian E. Ormesher,他曾一直担任高级副总裁,负责全球人力资源(2014年9月以来)。加入公司之前,他曾担任Carlsberg Breweries A/S的西欧人力资源副总裁(从2012年10月到2014年9月)。从2011年1月到2012年9月,他曾担任Carlsberg Breweries公司的副总裁,负责亚洲人力资源。此前,他曾任职SABMiller公司12年,在那里他曾担任多种人力资源和组织开发职务,并不断被提拔,包括中国企业人力资源董事,最终担任集团营销董事(2008年10月至2011年1月)。
Ian E. Ormesher has been our Senior Vice President, Global Human Resources since September 2014. Before joining the Company, Mr. Ormesher served as the Vice President, Human Resources - Western Europe at Carlsberg Breweries A/S from October 2012 to September 2014. From January 2011 to September 2012 he was the Vice President, Human Resources - Asia at Carlsberg Breweries. Prior to that time, Mr. Ormesher spent 12 years with SABMiller, where he served in a variety of HR and organizational development roles of increasing responsibility, including as HR Director of its business in China, and ultimately as its Group Marketing Capability Director from October 2008 to January 2011.
Charles M. Urbain

Charles M. Urbain,他自2012年1月担任Mead Johnson Nutrition Company的股东关系高级副总裁和首席开发官。他的职责包括领导公司的全球人力资源职能。之前,他从2009年1月至2011年12月担任Mead Johnson Nutrition Company亚洲和欧洲区总裁,从1987年2月持续在Mead Johnson和BMS担任各种职务。从2008年6月至2009年1月,他担任北美,拉丁美洲和欧洲的高级副总裁。从2007年6月至2008年6月他担任北美和欧洲的高级副总裁。从2004年1月至2007年6月他担任国际高级副总裁,并从2001年1月至2004年1月,他担任拉美,加拿大和欧洲的高级副总裁。


Charles M. Urbain has been Mead Johnson Nutrition Company's Executive Vice President and Chief Operating Officer since September 2015. He previously served as the Interim Chief Financial Officer from March 2015 through August 2015 as well as the serving as the Interim Controller and Treasurer from May 2015 through August 2015. Before holding these positions, Mr. Urbain had served as Mead Johnson Nutrition Company's Senior Vice President, Stakeholder Relations and Chief Development Officer since January 2012 which role included leadership of the Company's global human resources function. Mr. Urbain previously had been Mead Johnson Nutrition Company's President, Asia and Europe from January 2009 through December 2011 and has been employed continuously by Mead Johnson or BMS since February 1987 in various capacities. From June 2008 to January 2009 he served as Senior Vice President, North America, Latin America and Europe. From June 2007 to June 2008 Mr. Urbain served as Senior Vice President, North America and Europe. From January 2004 to June 2007 Mr. Urbain served as Senior Vice President, International, and from January 2001 to January 2004 he served as Senior Vice President, Latin America, Canada and Europe. From January 1999 to December 2000 Mr. Urbain served as Chief Financial Officer of the Mead Johnson division of BMS.
Charles M. Urbain,他自2012年1月担任Mead Johnson Nutrition Company的股东关系高级副总裁和首席开发官。他的职责包括领导公司的全球人力资源职能。之前,他从2009年1月至2011年12月担任Mead Johnson Nutrition Company亚洲和欧洲区总裁,从1987年2月持续在Mead Johnson和BMS担任各种职务。从2008年6月至2009年1月,他担任北美,拉丁美洲和欧洲的高级副总裁。从2007年6月至2008年6月他担任北美和欧洲的高级副总裁。从2004年1月至2007年6月他担任国际高级副总裁,并从2001年1月至2004年1月,他担任拉美,加拿大和欧洲的高级副总裁。
Charles M. Urbain has been Mead Johnson Nutrition Company's Executive Vice President and Chief Operating Officer since September 2015. He previously served as the Interim Chief Financial Officer from March 2015 through August 2015 as well as the serving as the Interim Controller and Treasurer from May 2015 through August 2015. Before holding these positions, Mr. Urbain had served as Mead Johnson Nutrition Company's Senior Vice President, Stakeholder Relations and Chief Development Officer since January 2012 which role included leadership of the Company's global human resources function. Mr. Urbain previously had been Mead Johnson Nutrition Company's President, Asia and Europe from January 2009 through December 2011 and has been employed continuously by Mead Johnson or BMS since February 1987 in various capacities. From June 2008 to January 2009 he served as Senior Vice President, North America, Latin America and Europe. From June 2007 to June 2008 Mr. Urbain served as Senior Vice President, North America and Europe. From January 2004 to June 2007 Mr. Urbain served as Senior Vice President, International, and from January 2001 to January 2004 he served as Senior Vice President, Latin America, Canada and Europe. From January 1999 to December 2000 Mr. Urbain served as Chief Financial Officer of the Mead Johnson division of BMS.
Dirk Hondmann

Dirk Hondmann,他自2005年10月加入Mead Johnson一直担任我们的全球研究和发展高级副总裁。从2002年10月至2005年10月他担任Slimfast公司的研究和开发副总裁,Slimfast属于联合利华集团的联属公司,联合利华是食品,家庭护理和个人护理产品的国际制造商。


Dirk Hondmann has been our Chief Scientific Officer since October 2014 prior to which time he served as our Senior Vice President, Global Research and Development since joining Mead Johnson in October 2005. From October 2002 to October 2005 Mr. Hondmann served as vice president, research and development of Slimfast, an affiliate of the Unilever Group, an international manufacturer of food, home care, and personal care products.
Dirk Hondmann,他自2005年10月加入Mead Johnson一直担任我们的全球研究和发展高级副总裁。从2002年10月至2005年10月他担任Slimfast公司的研究和开发副总裁,Slimfast属于联合利华集团的联属公司,联合利华是食品,家庭护理和个人护理产品的国际制造商。
Dirk Hondmann has been our Chief Scientific Officer since October 2014 prior to which time he served as our Senior Vice President, Global Research and Development since joining Mead Johnson in October 2005. From October 2002 to October 2005 Mr. Hondmann served as vice president, research and development of Slimfast, an affiliate of the Unilever Group, an international manufacturer of food, home care, and personal care products.
James Jeffrey Jobe

James Jeffrey Jobe,他自2005年11月一直担任我们全球供应链的高级副总裁,自1988年一职在Mead Johnson工作。2003年5月至2005年11他担任北美供应链高级总监。从2000年3月至2003年5他担任国际供应链高级总监。


James Jeffrey Jobe has been our Senior Vice President, Global Operations since December 2016 before which time he served as our Senior Vice President, Technical Operations since October 2014. Previously, Mr. Jobe served as our Senior Vice President, Global Supply Chain since November 2005. Mr. Jobe has been continuously employed by Mead Johnson since 1988. From May 2003 to November 2005 Mr. Jobe served as Senior Director, North America Supply Chain. From March 2000 to May 2003 Mr. Jobe served as Senior Director, International Supply Chain.
James Jeffrey Jobe,他自2005年11月一直担任我们全球供应链的高级副总裁,自1988年一职在Mead Johnson工作。2003年5月至2005年11他担任北美供应链高级总监。从2000年3月至2003年5他担任国际供应链高级总监。
James Jeffrey Jobe has been our Senior Vice President, Global Operations since December 2016 before which time he served as our Senior Vice President, Technical Operations since October 2014. Previously, Mr. Jobe served as our Senior Vice President, Global Supply Chain since November 2005. Mr. Jobe has been continuously employed by Mead Johnson since 1988. From May 2003 to November 2005 Mr. Jobe served as Senior Director, North America Supply Chain. From March 2000 to May 2003 Mr. Jobe served as Senior Director, International Supply Chain.
Patrick M. Sheller

Patrick M. Sheller是柯达公司(Kodak)的法律总顾问、董事会秘书兼首席行政官。他于2011年被任命为柯达公司(Kodak)的法律总顾问,并于2009年担任董事会秘书。在2012年2月,他被任命为首席行政官并被董事会选举为高级副总裁。作为法律总顾问,他主要负责公司全球范围内的法律部门,包括其知识产权法律组织,并负责为高级管理人员和董事会提供法律咨询。作为公司秘书,Sheller负责柯达公司(Kodak)的管理流程。他确保董事会依法履行其受托责任的适当建议和资源,以及确保本公司的公司记录能反映了董事会的动态。他是董事会和高级管理层有关联邦证券法律和法规的首席顾问。作为首席执行官, Sheller同样也负责人力资源、通讯及公共事务、全球信息系统、企业审计、健康安全和可持续发展环境等企业职能事务。Sheller法律、人事、交流和其他功能方面的工作,并成功翻开了柯达第11次历史新篇章,于2013年9月3日成功完成重组。Sheller继续监督柯达(Kodak)的转型进入聚焦成像业务的领先技术。Sheller在1993年加入柯达公司,并担任该公司的前身Health Group的部门。从1999年到2004年,他担任柯达的首席反垄断律师。从2000年至2004,Sheller是以欧洲为基础和并为柯达欧洲、非洲及中东地区的业务做商业法律争论的咨询。然后他回到了柯达的罗彻斯特总部,承担柯达的医疗信息系统业务的业务发展和经营方面的职务。从2005年至2011年,Sheller担任公司首席合规官。他于2009年被选为董事会秘书并于2011年担任副总法律顾问。Sheller具有圣劳伦斯大学(St. Lawrence University)的经济和政府方向的学士学位、联合大学奥尔巴尼法学院(Albany Law School of Union University)的法学博士学位。


Patrick M. Sheller has been our Senior Vice President, General Counsel and Secretary since January 2015. Prior to joining the Company, Mr. Sheller served as Senior Vice President, General Counsel, Secretary and Chief Administrative Officer of Eastman Kodak Company ‘‘Kodak’’. He served as Kodak’s General Counsel since 2011 as its Chief Administrative Officer since 2012 and as Secretary to Kodak’s Board of Directors since 2009. In 2011 Mr. Sheller was named Kodak’s Deputy General Counsel, and from 2005 to 2011 he served as their Chief Compliance Officer. Prior to that time, Mr. Sheller held various senior counsel roles with Kodak, including Chief Antitrust Counsel and division counsel to the Health Group and international commercial counsel to the Europe, Africa & Middle East Region. He also held operational roles in Kodak’s Health Group as Director of Strategic Planning and Business Development of the Health Care Information Systems business and Director of Operations for the Health Informatics business.
Patrick M. Sheller是柯达公司(Kodak)的法律总顾问、董事会秘书兼首席行政官。他于2011年被任命为柯达公司(Kodak)的法律总顾问,并于2009年担任董事会秘书。在2012年2月,他被任命为首席行政官并被董事会选举为高级副总裁。作为法律总顾问,他主要负责公司全球范围内的法律部门,包括其知识产权法律组织,并负责为高级管理人员和董事会提供法律咨询。作为公司秘书,Sheller负责柯达公司(Kodak)的管理流程。他确保董事会依法履行其受托责任的适当建议和资源,以及确保本公司的公司记录能反映了董事会的动态。他是董事会和高级管理层有关联邦证券法律和法规的首席顾问。作为首席执行官, Sheller同样也负责人力资源、通讯及公共事务、全球信息系统、企业审计、健康安全和可持续发展环境等企业职能事务。Sheller法律、人事、交流和其他功能方面的工作,并成功翻开了柯达第11次历史新篇章,于2013年9月3日成功完成重组。Sheller继续监督柯达(Kodak)的转型进入聚焦成像业务的领先技术。Sheller在1993年加入柯达公司,并担任该公司的前身Health Group的部门。从1999年到2004年,他担任柯达的首席反垄断律师。从2000年至2004,Sheller是以欧洲为基础和并为柯达欧洲、非洲及中东地区的业务做商业法律争论的咨询。然后他回到了柯达的罗彻斯特总部,承担柯达的医疗信息系统业务的业务发展和经营方面的职务。从2005年至2011年,Sheller担任公司首席合规官。他于2009年被选为董事会秘书并于2011年担任副总法律顾问。Sheller具有圣劳伦斯大学(St. Lawrence University)的经济和政府方向的学士学位、联合大学奥尔巴尼法学院(Albany Law School of Union University)的法学博士学位。
Patrick M. Sheller has been our Senior Vice President, General Counsel and Secretary since January 2015. Prior to joining the Company, Mr. Sheller served as Senior Vice President, General Counsel, Secretary and Chief Administrative Officer of Eastman Kodak Company ‘‘Kodak’’. He served as Kodak’s General Counsel since 2011 as its Chief Administrative Officer since 2012 and as Secretary to Kodak’s Board of Directors since 2009. In 2011 Mr. Sheller was named Kodak’s Deputy General Counsel, and from 2005 to 2011 he served as their Chief Compliance Officer. Prior to that time, Mr. Sheller held various senior counsel roles with Kodak, including Chief Antitrust Counsel and division counsel to the Health Group and international commercial counsel to the Europe, Africa & Middle East Region. He also held operational roles in Kodak’s Health Group as Director of Strategic Planning and Business Development of the Health Care Information Systems business and Director of Operations for the Health Informatics business.
James E. Shiah

James E. Shiah,他是科蒂公司的高级副总裁,首席会计及合规官。在这个位置上,他是公司的主要会计人员,负责监督各种活动,包括财务报告,内部财务系统及其他合规计划。他拥有30年的多元化的全球金融经验,包括公共会计,财务操作和各种企业员工岗位。在2011年成为高级副总裁,首席会计师及监察主任前,他担任财务高级副总裁兼全球财务总监从2006至2011年,副总裁兼公司财务总监从2001至2006年。于2001年加入公司前,他曾在不同的跨国公司担任财务领导职务,包括的纳贝斯克公司的北拉丁美洲地区首席财务官,后来为首席内部审计师;和在施贵宝公司的内部审计部门工作。他的职业生涯开始于德勤会计师事务所于1982年。他毕业于纽约州立大学布法罗雅各布管理学院,在那里他获得了会计及财务的工商管理硕士学位。他获得纽约州立大学布法罗分校的工商管理理学学士学位,并且是在纽约州的一名注册会计师。


James E. Shiah has been our Senior Vice President, Finance and Controller since December 2015 prior to which time he served as our Senior Vice President, Finance since June 2015. Before holding this position, Mr. Shiah served as the Senior Vice President, Chief Accounting and Compliance Officer of Coty Inc. from 2011 to 2014. In this position, Mr. Shiah was Coty’s principal accounting officer responsible for overseeing various activities including financial reporting, systems of internal control and other compliance programs. Mr. Shiah was Coty’s Senior Vice President Finance and Global Controller from 2006 to 2011 and its Vice President and Corporate Controller from 2001 to 2006. Mr. Shiah began his career at Deloitte & Touche and is a Certified Public Accountant.
James E. Shiah,他是科蒂公司的高级副总裁,首席会计及合规官。在这个位置上,他是公司的主要会计人员,负责监督各种活动,包括财务报告,内部财务系统及其他合规计划。他拥有30年的多元化的全球金融经验,包括公共会计,财务操作和各种企业员工岗位。在2011年成为高级副总裁,首席会计师及监察主任前,他担任财务高级副总裁兼全球财务总监从2006至2011年,副总裁兼公司财务总监从2001至2006年。于2001年加入公司前,他曾在不同的跨国公司担任财务领导职务,包括的纳贝斯克公司的北拉丁美洲地区首席财务官,后来为首席内部审计师;和在施贵宝公司的内部审计部门工作。他的职业生涯开始于德勤会计师事务所于1982年。他毕业于纽约州立大学布法罗雅各布管理学院,在那里他获得了会计及财务的工商管理硕士学位。他获得纽约州立大学布法罗分校的工商管理理学学士学位,并且是在纽约州的一名注册会计师。
James E. Shiah has been our Senior Vice President, Finance and Controller since December 2015 prior to which time he served as our Senior Vice President, Finance since June 2015. Before holding this position, Mr. Shiah served as the Senior Vice President, Chief Accounting and Compliance Officer of Coty Inc. from 2011 to 2014. In this position, Mr. Shiah was Coty’s principal accounting officer responsible for overseeing various activities including financial reporting, systems of internal control and other compliance programs. Mr. Shiah was Coty’s Senior Vice President Finance and Global Controller from 2006 to 2011 and its Vice President and Corporate Controller from 2001 to 2006. Mr. Shiah began his career at Deloitte & Touche and is a Certified Public Accountant.